ASTERA BIO
Astera Bio applies a private equity investment approach to public equities, evaluating the science,
technology, and the operational likelihood of success.
Strategy
Concentrated, long-biased portfolio of small to mid-cap cell and gene therapy companies that exhibit cutting-edge science and/or platform technology anchored by a minority of established companies implementing efficient innovation to stay relevant and profitable.
ABOUT
Who We Are
Astera Bio borrows its name from the plant genus of Asteraceae, discovered by Ynes Mexia, arguably the most accomplished plant collector of her time who began her career in botany in her mid-50s. She was what would be called an extremely successful “Encore Entrepreneur” today.
Meet Our Team
Our in-depth expertise in biotech success criteria including science, medicine, drug development, regulatory, clinical operations, and commercialization allows for an unbiased selection of undervalued early-stage cell and gene therapy companies for investment.
LATEST NEWS
Find the latest news on Astera
STRATEGY & SCIENCE
Astera Bio focuses on innovative preclinical and early clinical companies in the cell and gene therapy (CGTx) space. Figure 1 below depicts the large amount of attrition from drug development and its relevant phases (from target validation to drug application submission). It is at these early critical junctures (from preclinical to Phase 1/2 readouts) that […]
THE POST COVID-19 WORLD: A FOCUS ON BIOTECH
At Astera Biofunds, we have always asserted that the future of how disease is treated will be dramatically different than what we have been accustomed to since the days of penicillin and aspirin. Cell and gene therapy ushers in a new treatment paradigm, where reprogramming biology to fight and prevent disease is tailored to an […]